Ranbaxy Laboratories has reported a consolidated net sales of $542m for the first quarter ended March 31, 2010, an increase of 65 per cent, compared to $313m for the comparable period in 2009.
For the first quarter of 2010, Ranbaxy Laboratories has posted a EBITDA of $298m, compared to a loss of $201m for the prior year period. Profit after tax (PAT) was $210m, compared to loss of $153m for the year ago period. Operational PAT, excluding forex translations, was $143m, compared to loss of $5m for the prior year period.
Atul Sobti, CEO and managing director of Ranbaxy, said: "Solid growth in key geographies, along with optimal delivery value from First-to-File opportunities in the US, ensured that we achieved yet another quarter of strong operational performance. We also launched Project Viraat, a comprehensive program aimed at India leadership, in January, 2010."